APP下载

不同剂量辛伐他汀治疗老年高血压合并高脂血症的临床疗效及安全性分析

2020-06-01王庆月

中国实用医药 2020年13期
关键词:辛伐他汀安全性高血压

王庆月

【摘要】 目的 分析不同剂量辛伐他汀治疗老年高血压合并高脂血症的临床疗效和安全性。

方法 124例老年高血压合并高脂血症患者, 按照用药剂量不同分为治疗A组与治疗B组, 各62例。

治疗A组应用大剂量辛伐他汀治疗, 治疗B组应用低剂量辛伐他汀治疗。比较两组治疗前后血脂指标、肝功能指标临床疗效和安全性。结果 治疗后, 两组患者高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)及总胆固醇(TC)水平均较本组治疗前改善, 且治疗A组患者 HDL-C(1.60±1.05)mmol/L、LDL-C(3.85±0.83)mmol/L、TG(1.15±0.74)mmol/L及TC(4.52±1.23)mmol/L均優于治疗B组的(1.28±0.09)、(5.04±0.73)、(1.79±0.83)、(5.57±1.38)mmol/L, 差异具有统计学意义(P<0.05)。治疗A组患者治疗总有效率95.16%高于治疗B组的82.26%, 差异具有统计学意义(P<0.05)。两组患者治疗前后谷草转氨酶(AST)、谷丙转氨酶(ALT)、肌酸激酶(CK)水平组间比较, 差异均无统计学意义(P>0.05)。治疗A组不良反应发生率8.06%与治疗B组的6.45%比较, 差异无统计学意义(P>0.05)。结论 老年高血压合并高脂血症患者更适合应用大剂量辛伐他汀, 能够获得更佳的血脂调节效果和临床疗效, 且能够保障用药安全性。

【关键词】 高血压;高脂血症;辛伐他汀;大剂量;安全性

DOI:10.14163/j.cnki.11-5547/r.2020.13.007

Analysis of clinical efficacy and safety of different doses of simvastatin in the treatment of elderly hypertension with hyperlipidemia   WANG Qing-yue. Department of Pharmacy, Yanggu County Peoples Hospital, Liaocheng 252300, China

【Abstract】 Objective   To analyze the clinical efficacy and safety of different doses of simvastatin in the treatment of elderly hypertension with hyperlipidemia. Methods   A total of 124 elderly patients with hypertension with hyperlipidemia were divided into treatment group A and treatment group B by different drug doses, with

62 cases in each group. Treatment group A was treated by high-dose simvastatin, and treatment group B was treated by low-dose simvastatin. The blood lipid indicators  and liver function indicators before and after treatment, clinical efficacy and safety were compared between the two groups. Results   After treatment, the levels of high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglyceride (TG) and total cholesterol (TC) of the two groups were better than those before treatment of the same group, and HDL-C (1.60±1.05) mmol/L, LDL-C (3.85±0.83) mmol/L, TG (1.15±0.74) mmol/L and TC (4.52±

1.23) mmol/L of treatment group A was better than those of treatment group B (1.28±0.09), (5.04±0.73), (1.79±0.83) and (5.57±1.38)mmol/L. The difference was statistically significant (P<0.05). The total effective rate of treatment 95.16% of treatment group A was higher than that of treatment group B 82.26%, and the difference was statistically significant (P<0.05). Before and after treatment, there was no statistically significant difference in levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CK) between the two groups (P>0.05). The incidence of adverse reactions of treatment group A was 8.06%, which had no statistically significant difference compared with that of treatment group B 6.45% (P>0.05). Conclusion   Elderly patients with hypertension and hyperlipidemia are more suitable for high-dose simvastatin, which can obtain better blood lipid regulation effect and clinical efficacy, and can ensure the safety of medication.

【Key words】 Hypertension; Hyperlipidemia; Simvastatin; High-dose; Safety

我国有数量庞大的高血压患者群体, 其中合并高脂血症的老年患者所占比重较大, 这类患者不仅代表治疗难度上升, 也存在了更多的风险因素, 有诱发更严重心脑血管疾病的几率[1, 2]。帮助患者有效控制血压、调节血脂水平是治疗重点, 血脂调节方面首选他汀类药物, 其中辛伐他汀应用率较高[3]。此次研究分析了不同剂量辛伐他汀治疗老年高血压合并高脂血症的临床疗效和安全性, 总结报告如下。

1 资料与方法

1. 1 一般资料 选择2018年1月~2019年3月本院收治的124例老年高血压合并高脂血症患者, 按照患者用药剂量的不同分为治疗A组与治疗B组, 各62例。

登录APP查看全文

猜你喜欢

辛伐他汀安全性高血压
两款输液泵的输血安全性评估
新染料可提高电动汽车安全性
全国高血压日
如何把高血压“吃”回去?
高血压,并非一降了之
ApplePay横空出世 安全性遭受质疑 拿什么保护你,我的苹果支付?
辛伐他汀对高血压并发阵发性心房颤动的作用及机制
辛伐他汀联合曲美他嗪对糖尿病伴冠心病的影响
Imagination发布可实现下一代SoC安全性的OmniShield技术
脑梗死应用辛伐他汀联合抗栓治疗的临床观察